Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received an average rating of "Moderate Buy" from the ten analysts that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $55.30.

A number of equities analysts have weighed in on CLDX shares. UBS Group started coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price target on the stock. The Goldman Sachs Group lowered their price target on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a report on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective on the stock. Morgan Stanley initiated coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Friday, February 28th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Barclays PLC increased its stake in Celldex Therapeutics by 140.7% during the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after buying an additional 76,207 shares during the period. Mirador Capital Partners LP grew its stake in shares of Celldex Therapeutics by 2.9% during the fourth quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company's stock valued at $3,020,000 after acquiring an additional 3,345 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Celldex Therapeutics by 24.4% during the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after acquiring an additional 4,967 shares during the last quarter. KBC Group NV lifted its stake in shares of Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares in the last quarter. Finally, Sovran Advisors LLC purchased a new position in Celldex Therapeutics in the fourth quarter valued at about $2,867,000.

Celldex Therapeutics Stock Down 0.2 %

Shares of NASDAQ:CLDX traded down $0.05 during midday trading on Friday, reaching $20.66. The company's stock had a trading volume of 598,699 shares, compared to its average volume of 884,988. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -8.04 and a beta of 1.59. The business has a 50 day moving average price of $19.09 and a 200 day moving average price of $23.17. Celldex Therapeutics has a 1 year low of $14.40 and a 1 year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Sell-side analysts anticipate that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.